Real time in vitro studies of doxorubicin release from PHEMA nanoparticles
1Bose Memorial Research Laboratory, Department of Chemistry, Government Autonomous Science College, Jabalpur (MP)-482001, India. akbmrl@yahoo.co.in.
Background:
Many anticancer agents have poor water solubility and therefore the development of novel delivery systems for such molecules has received significant attention. Nanocarriers show great potential in delivering therapeutic agents into the targeted organs or cells and have recently emerged as a promising approach to cancer treatments. The aim of this study was to prepare and use poly-2-hydroxyethyl methacrylate (PHEMA) nanoparticles for the controlled release of the anticancer drug doxorubicin.
Results:
PHEMA nanoparticles have been synthesized and characterized using FTIR and scanning electron microscopy (SEM), particle size analysis and surface charge measurements. We also studied the effects of various parameters such as percent loading of drugs, chemical architecture of the nanocarriers, pH, temperature and nature of the release media on the release profiles of the drug. The chemical stability of doxorubicin in PBS was assessed at a range of pH.
Conclusion:
Suspension polymerization of 2-hydroxyethyl methacrylate (HEMA) results in the formation of swellable nanoparticles of defined composition. PHEMA nanoparticles can potentially be used for the controlled release of the anticancer drug doxorubicin.
Insights
Poly-2-hydroxyethyl methacrylate (PHEMA) nanoparticles were developed for controlled release of doxorubicin. These novel nanocarriers show promise for targeted cancer therapy delivery.
Area of Science:
- Biomaterials Science
- Nanotechnology
- Drug Delivery Systems
Background:
- Poor water solubility of anticancer agents necessitates advanced delivery systems.
- Nanocarriers offer potential for targeted delivery of therapeutics to organs and cells.
- Nanoparticles are emerging as a promising strategy in cancer treatment.
Purpose of the Study:
- To synthesize and characterize poly-2-hydroxyethyl methacrylate (PHEMA) nanoparticles.
- To evaluate PHEMA nanoparticles for the controlled release of doxorubicin.
- To investigate factors influencing doxorubicin release from PHEMA nanocarriers.
Main Methods:
- Suspension polymerization of 2-hydroxyethyl methacrylate (HEMA).
- Characterization using FTIR, SEM, particle size analysis, and surface charge measurements.
- In vitro drug release studies under varying conditions (pH, temperature, media).
Main Results:
- Successfully synthesized and characterized PHEMA nanoparticles.
- Demonstrated controlled release of doxorubicin from PHEMA nanocarriers.
- Analyzed the influence of drug loading, nanocarrier architecture, and environmental factors on drug release profiles.
Conclusions:
- Suspension polymerization yields swellable PHEMA nanoparticles with defined composition.
- PHEMA nanoparticles demonstrate potential for controlled delivery of doxorubicin.
- These nanoparticles represent a viable approach for enhancing anticancer drug efficacy.
